SPY002 Posts Highly Positive Phase 2 Results for Ulcerative Colitis
SYRE has more than doubled off its 52-week low of $13.93.
Summary
Spyre Therapeutics announced highly positive Phase 2 SKYLINE Part A results for its drug candidate SPY002 in ulcerative colitis. The trial met its primary endpoint, showing a significant 10.7-point reduction in the Robarts Histopathology Index (p<0.0001), alongside high clinical remission (33%) and endoscopic improvement (42%) rates. This news follows an 8-K filing minutes earlier and builds on the company's strong pipeline, which also saw positive Phase 2 data for SPY001 in April. These robust results validate SPY002's potential in a competitive therapeutic area and are critical for a company trading near its 52-week high. Enrollment for Part B combination arms is currently underway.
At the time of this announcement, SYRE was trading at $82.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7B. The 52-week trading range was $13.93 to $84.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.